Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M130,459Revenue $M37,075Net Margin (%)12.9Z-Score2.5
Enterprise Value $M69,757EPS $1.8Operating Margin %18.0F-Score7
P/E(ttm))28.0Cash Flow Per Share $0Pre-tax Margin (%)16.8Higher ROA y-yY
Price/Book2.210-y EBITDA Growth Rate %0Quick Ratio1.3Cash flow > EarningsY
Price/Sales3.65-y EBITDA Growth Rate %0Current Ratio1.8Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %7.5ROA % (ttm)7.7Higher Current Ratio y-yY
Dividend Yield %3.9Insider Buy (3m)0ROE % (ttm)13.3Less Shares Outstanding y-yN
Payout Ratio %84.0Shares Outstanding M2,639ROI % (ttm)4.2Gross Margin Increase y-yY

Gurus Latest Trades with SNY

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SNYHOTCHKIS & WILEY 2014-12-31 Add0.29%$44.4 - $55
($48.49)
$ 49.442%Add 18.16%11,692,693
SNYNWQ Managers 2014-12-31 Add0.29%$44.4 - $55
($48.49)
$ 49.442%Add 22.12%2,941,923
SNYCharles Brandes 2014-12-31 Add0.21%$44.4 - $55
($48.49)
$ 49.442%Add 14.36%2,571,795
SNYJames Barrow 2014-12-31 Add0.15%$44.4 - $55
($48.49)
$ 49.442%Add 8.87%30,804,459
SNYDavid Dreman 2014-12-31 Buy $44.4 - $55
($48.41)
$ 49.442%New holding1,102
SNYBill Nygren 2014-09-30 Add0.27%$50.89 - $57.29
($53.73)
$ 49.44-9%Add 14.55%5,670,000
SNYJean-Marie Eveillard 2014-09-30 Reduce-0.07%$50.89 - $57.29
($53.73)
$ 49.44-9%Reduce -94.39%34,157
SNYPRIMECAP Management 2014-09-30 Add0.05%$50.89 - $57.29
($53.73)
$ 49.44-9%Add 29.21%3,891,356
SNYNWQ Managers 2014-06-30 Reduce-1.31%$51.23 - $54.54
($53.08)
$ 49.44-7%Reduce -52.34%2,602,503
SNYBill Nygren 2014-06-30 Add0.9%$51.23 - $54.54
($53.08)
$ 49.44-7%Add 90.38%4,950,000
SNYScott Black 2014-06-30 Reduce-0.39%$51.23 - $54.54
($53.08)
$ 49.44-7%Reduce -27.57%178,985
SNYJohn Hussman 2014-06-30 Sold Out -0.09%$51.23 - $54.54
($53.08)
$ 49.44-7%Sold Out0
SNYPRIMECAP Management 2014-06-30 Add0.03%$51.23 - $54.54
($53.08)
$ 49.44-7%Add 21.59%3,011,646
SNYScott Black 2014-03-31 Buy 1.4%$47.77 - $53.63
($50.64)
$ 49.44-2%New holding247,100
SNYBill Nygren 2014-03-31 Buy 1.1%$47.77 - $53.63
($50.68)
$ 49.44-3%New holding2,600,000
SNYHOTCHKIS & WILEY 2014-03-31 Add0.75%$47.77 - $53.63
($50.68)
$ 49.44-3%Add 65.83%9,804,594
SNYJames Barrow 2014-03-31 Add0.39%$47.77 - $53.63
($50.68)
$ 49.44-3%Add 22.72%27,790,116
SNYNWQ Managers 2014-03-31 Reduce-0.17%$47.77 - $53.63
($50.68)
$ 49.44-3%Reduce -6.39%5,460,055
SNYHOTCHKIS & WILEY 2013-12-31 Add0.27%$48.75 - $54
($51.57)
$ 49.44-4%Add 23.53%5,912,375
SNYCharles Brandes 2013-12-31 Add0.2%$48.75 - $54
($51.57)
$ 49.44-4%Add 18.29%2,013,300
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SNY is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


SNY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Sanofi10% Owner 2015-01-29Buy97,118$95-48.63view
Sanofi10% Owner 2015-01-26Buy843,699$2240.11-97.82view
Sanofi10% Owner 2015-01-22Buy196,251$93.17-47.62view
Sanofi10% Owner 2014-03-25Buy344,448$66.88-27.03view
Sanofi10% Owner 2014-02-04Buy1,303,780$7.67536.25view

Press Releases about SNY :

    Quarterly/Annual Reports about SNY:

      News about SNY:

      Articles On GuruFocus.com
      Scottrade Mar 23 2015 
      Pfizer In The Process Of Making Path Breaking Vaccine Mar 18 2015 
      Oh là là! Looking for Dividend Yield? Explore France Feb 27 2015 
      FDA Approves Sanofi’s New Diabetes Drug Feb 27 2015 
      Dodge & Cox 2014 Equity Year in Review Feb 19 2015 
      The Reasons That Make Pfizer A Worthy Hold. Feb 05 2015 
      Causeway Capital Global Value Equity Q4 2014 Commentary Feb 04 2015 
      Causeway International Value Fund Q4 2014 Commentary Jan 20 2015 
      Dodge & Cox's Stock Fund Q4 2014 Commentary Jan 20 2015 
      Guru Stocks at 52-Week Lows: GOOG, VZ, HSBC, SNY, TOT Jan 12 2015 


      More From Other Websites
      Sanofi Reveals Cerdelga Data, FDA OK's Quadracel Vaccine - Analyst Blog Mar 26 2015
      Genzyme Convenes Sixth Annual Gaucher Leadership Forum Mar 26 2015
      ENCORE Clinical Data Published in The Lancet Suggest Treatment with Oral Maintenance Therapy... Mar 25 2015
      Sanofi Pasteur Announces FDA Approval of Quadracel DTaP-IPV Vaccine for Children 4 through 6 Years... Mar 25 2015
      Isis Pharmaceuticals Reports Phase I Data on Lipid Candidate - Analyst Blog Mar 24 2015
      11 Promising New Drugs Expected to Make Billions in Sales Mar 23 2015
      Amicus to Seek for Migalastat's Approval in the U.S., EU - Analyst Blog Mar 20 2015
      Sanofi Inks Multi-Component Strategic Deal with Evotec - Analyst Blog Mar 20 2015
      Goldman Downgrade Makes MannKind A Buy Mar 20 2015
      Evotec and Sanofi Sign Definitive Agreement for Major Multi-Component Strategic Alliance Mar 19 2015
      Mark Levin to be honored with MassBio's annual Termeer award Mar 19 2015
      Amicus Up As FDA, EU Green-light Quick Drug Filings Mar 19 2015
      Novo Nordisk On Diversity In Diabetes Trials: "We Could Do Better" Mar 19 2015
      5 Breakout Stocks to Trade for Gains After the Fed's Bombshell Mar 19 2015
      Sanofi Announces Top-Line Results for Cardiovascular Outcomes Study of Lyxumia® (lixisenatide) Mar 19 2015
      Sanofi Announces Top-Line Results for Cardiovascular Outcomes Study of Lyxumia(r) (lixisenatide) Mar 19 2015
      Investors Relieved? Akorn Stock Retakes 50-Day Line Mar 18 2015
      To sell or not to sell: United Therapeutics faces choice with potential fast-track drug voucher Mar 18 2015
      The Temptation of International Dividend ETFs Mar 18 2015
      Regeneron Hits a 52-Week High on Positive Praluent Data - Analyst Blog Mar 18 2015

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK